Icatibant Injection

Generic name: icatibant acetate
Dosage form: injection, solution
Drug class:Hereditary angioedema agents

Medically reviewed by Drugs.com. Last updated on Jun 1, 2021.

Indications and Usage for Icatibant Injection

SAJAZIR (icatibant) injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Icatibant Injection Dosage and Administration

Recommended Dosing

The recommended dose of SAJAZIR is 30 mg administered by subcutaneous (SC) injection in the abdominal area. Additional doses may be administered at intervals of at least 6 hours if response is inadequate or if symptoms recur. No more than 3 doses may be administered in any 24 hour period.

Administration Instructions

Icatibant Injection should be inspected visually for particulate matter and discoloration prior to administration. The drug solution should be clear and colorless. Do not administer if the product contains particulates or is discolored.

Attach the provided 25 gauge needle to the syringe hub and screw on securely. Do not use a different needle. Disinfect the injection site and administer SAJAZIR by subcutaneous injection over at least 30 seconds.

Patients may self-administer SAJAZIR upon recognition of symptoms of an HAE attack after training under the guidance of a healthcare professional [see Patient Counseling Information (17)].

Dosage Forms and Strengths

SAJAZIR is supplied in a prefilled syringe delivering 30 mg icatibant. Each syringe delivers 3 mL solution with a concentration of 10 mg per mL.

Contraindications

None.

Warnings and Precautions

Laryngeal Attacks

Given the potential for airway obstruction during acute laryngeal HAE attacks,...